<DOC>
	<DOCNO>NCT00740415</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Bortezomib may stop growth cancer cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , doxorubicin , dexamethasone , chlorambucil , work different way stop growth cancer cell , either kill cell stop divide . Giving combination chemotherapy together rituximab bortezomib may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together bortezomib , doxorubicin , dexamethasone , chlorambucil work first-line therapy treat old patient stage II , stage III , stage IV mantle cell lymphoma .</brief_summary>
	<brief_title>Rituximab , Bortezomib , Bendamustine , Dexamethasone , Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy rituximab , bortezomib , doxorubicin hydrochloride , dexamethasone , chlorambucil first-line therapy patient stage II-IV mantle cell lymphoma . Secondary - Determine complete response rate patient . - Determine efficacy , term complete overall response , F18 fludeoxyglucose scan . - Determine overall , disease-free , event-free survival patient . - Assess tolerability regimen patient . - Evaluate impact factor , describe previous protocol , response therapy survival . - Assess impact residual disease cerebrospinal fluid survival . OUTLINE : This multicenter study . Patients receive rituximab IV day 1 ( day 1 8 first course ) ; bortezomib IV day 1 , 4 , 8 , 11 ; doxorubicin hydrochloride IV continuously 24 hour day 1-4 ; dexamethasone IV day 1-4 ; oral chlorambucil day 20-29 . Treatment repeat every 5 week 4 course absence disease progression unacceptable toxicity . Patients achieve least 50 % response receive 2 additional course therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis mantle cell lymphoma Stage IIIV disease No neuromeningeal disease PATIENT CHARACTERISTICS : WHO performance status 02 No prior cancer except carcinoma situ cervix basal cell skin cancer LVEF &gt; 50 % HIVnegative Hepatitis B Cnegative No hepatocellular , renal , bone marrow insufficiency unrelated lymphoma PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>